AU2017259870B2 - Amide-substituted pyridinyltriazole derivatives and uses thereof - Google Patents

Amide-substituted pyridinyltriazole derivatives and uses thereof Download PDF

Info

Publication number
AU2017259870B2
AU2017259870B2 AU2017259870A AU2017259870A AU2017259870B2 AU 2017259870 B2 AU2017259870 B2 AU 2017259870B2 AU 2017259870 A AU2017259870 A AU 2017259870A AU 2017259870 A AU2017259870 A AU 2017259870A AU 2017259870 B2 AU2017259870 B2 AU 2017259870B2
Authority
AU
Australia
Prior art keywords
compound
general formula
group
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017259870A
Other languages
English (en)
Other versions
AU2017259870A1 (en
Inventor
Anja BUCHMÜLLER
Hana CERNECKA
Marie-Pierre Collin-Kropelin
Karoline DRÖBNER
Chantal FÜRSTNER
Peter Kolkhof
Axel Kretschmer
Klemens Lustig
Thomas MONDRITZKI
Thomas Neubauer
Elisabeth Pook
Heiko Schirmer
Carsten Schmeck
Hanna Tinel
Pierre Wasnaire
Matthias Beat WITTWER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AU2017259870A1 publication Critical patent/AU2017259870A1/en
Application granted granted Critical
Publication of AU2017259870B2 publication Critical patent/AU2017259870B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017259870A 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof Ceased AU2017259870B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03
EP16168165.5 2016-05-03
PCT/EP2017/060356 WO2017191102A1 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2017259870A1 AU2017259870A1 (en) 2018-11-15
AU2017259870B2 true AU2017259870B2 (en) 2021-07-15

Family

ID=55910850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017259870A Ceased AU2017259870B2 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Country Status (42)

Country Link
US (4) US9988367B2 (enExample)
EP (1) EP3452463B1 (enExample)
JP (1) JP6932140B2 (enExample)
KR (1) KR20190003655A (enExample)
CN (2) CN113121504A (enExample)
AR (1) AR108262A1 (enExample)
AU (1) AU2017259870B2 (enExample)
BR (1) BR112018072542A2 (enExample)
CA (1) CA3022749A1 (enExample)
CL (1) CL2018003105A1 (enExample)
CO (1) CO2018011933A2 (enExample)
CR (1) CR20180522A (enExample)
CU (1) CU24567B1 (enExample)
CY (1) CY1124084T1 (enExample)
DK (1) DK3452463T3 (enExample)
DO (1) DOP2018000240A (enExample)
EA (1) EA035596B1 (enExample)
EC (1) ECSP18081881A (enExample)
ES (1) ES2866109T3 (enExample)
GE (1) GEP20207158B (enExample)
HR (1) HRP20210648T1 (enExample)
HU (1) HUE053908T2 (enExample)
IL (1) IL262557B (enExample)
JO (1) JOP20170105B1 (enExample)
LT (1) LT3452463T (enExample)
MA (1) MA44851B1 (enExample)
MX (1) MX381787B (enExample)
NI (1) NI201800115A (enExample)
PE (1) PE20190116A1 (enExample)
PH (1) PH12018502268A1 (enExample)
PL (1) PL3452463T3 (enExample)
PT (1) PT3452463T (enExample)
RS (1) RS61771B1 (enExample)
SG (1) SG11201809752VA (enExample)
SI (1) SI3452463T1 (enExample)
SV (1) SV2018005771A (enExample)
TN (1) TN2018000368A1 (enExample)
TW (1) TWI772295B (enExample)
UA (1) UA123791C2 (enExample)
UY (1) UY37220A (enExample)
WO (1) WO2017191102A1 (enExample)
ZA (1) ZA201808131B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071500B (zh) * 2016-05-03 2021-05-18 拜耳制药股份公司 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法
EP3452457B1 (en) * 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
EP3763704A1 (en) 2016-05-03 2021-01-13 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
US10954197B2 (en) * 2017-03-08 2021-03-23 Yogee's Bioinnovations Private Limited Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
SG11202003049WA (en) 2017-10-24 2020-04-29 Bayer Ag Prodrugs of substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
US11230540B2 (en) 2017-10-24 2022-01-25 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
US20210016350A1 (en) * 2018-04-10 2021-01-21 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
WO2021132010A1 (ja) * 2019-12-24 2021-07-01 東京エレクトロン株式会社 成膜方法及び成膜システム
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
WO2024118667A1 (en) * 2022-11-29 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Eif4a1 inhibitors with antitumor activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104322A1 (de) * 2010-02-27 2011-09-01 Bayer Pharma Aktiengesellschaft Bis-arylverknüpfte aryltriazolone und ihre verwendung
WO2016071212A1 (en) * 2014-11-03 2016-05-12 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP3290657B2 (ja) 1991-05-01 2002-06-10 メルク エンド カムパニー インコーポレーテッド アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
EA003095B1 (ru) 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
CN1177835C (zh) 1998-07-24 2004-12-01 拜尔公司 取代的苯甲酰基环己二酮类化合物
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
CA2366858A1 (en) 1999-04-01 2000-10-12 Margaret Yuhua Chu-Moyer Sorbitol dehydrogenase inhibitors
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1606264B1 (en) 2003-03-14 2012-05-02 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin cgrp receptor antagonists
KR20060066141A (ko) 2003-06-27 2006-06-15 버글린 코퍼레이션 오브 워싱턴 사과 및 연한 코아를 가지거나 피트를 가진 다른 과일들을작은 응력을 가지고 정확하게 코아제거하고슬라이스절단하기 위한 기계
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
EP1722788A4 (en) 2004-03-08 2008-02-13 Wyeth Corp MODULATORS OF IONIC CHANNELS
BRPI0508532A (pt) 2004-03-08 2007-08-07 Wyeth Corp moduladores do canal de ìon
BRPI0510340A (pt) 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN103097387B (zh) 2010-07-09 2016-11-02 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
AU2011308403B2 (en) * 2010-10-01 2014-08-21 Taisho Pharmaceutical Co., Ltd. 1,2,4-triazolone derivative
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
HK1206031A1 (en) 2012-03-22 2015-12-31 生物区欧洲有限公司 Antibacterial compounds
EP3452457B1 (en) * 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
CN109071500B (zh) * 2016-05-03 2021-05-18 拜耳制药股份公司 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104322A1 (de) * 2010-02-27 2011-09-01 Bayer Pharma Aktiengesellschaft Bis-arylverknüpfte aryltriazolone und ihre verwendung
WO2016071212A1 (en) * 2014-11-03 2016-05-12 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
US10472348B2 (en) 2019-11-12
IL262557B (en) 2022-01-01
ZA201808131B (en) 2021-05-26
US20190144423A1 (en) 2019-05-16
EP3452463B1 (en) 2021-03-24
SG11201809752VA (en) 2018-12-28
JP2019514945A (ja) 2019-06-06
HUE053908T2 (hu) 2021-07-28
BR112018072542A2 (pt) 2019-03-26
CN109415347B (zh) 2021-05-07
CU24567B1 (es) 2022-01-13
MA44851B1 (fr) 2021-09-30
AR108262A1 (es) 2018-08-01
US20180251447A1 (en) 2018-09-06
PH12018502268A1 (en) 2019-07-15
CO2018011933A2 (es) 2018-11-22
TN2018000368A1 (en) 2020-06-15
MX2018013335A (es) 2019-05-09
KR20190003655A (ko) 2019-01-09
US20170320854A1 (en) 2017-11-09
TW201806941A (zh) 2018-03-01
UA123791C2 (uk) 2021-06-02
CY1124084T1 (el) 2022-05-27
EA201892505A1 (ru) 2019-04-30
IL262557A (en) 2018-12-31
CN109415347A (zh) 2019-03-01
US9988367B2 (en) 2018-06-05
LT3452463T (lt) 2021-04-26
CN113121504A (zh) 2021-07-16
AU2017259870A1 (en) 2018-11-15
EP3452463A1 (en) 2019-03-13
HRP20210648T1 (hr) 2021-05-28
RS61771B1 (sr) 2021-05-31
NI201800115A (es) 2019-03-14
GEP20207158B (en) 2020-10-12
JOP20170105B1 (ar) 2022-03-14
DOP2018000240A (es) 2019-03-15
PE20190116A1 (es) 2019-01-16
UY37220A (es) 2017-11-30
SI3452463T1 (sl) 2021-07-30
CR20180522A (es) 2019-01-15
SV2018005771A (es) 2019-01-04
EA035596B1 (ru) 2020-07-14
PL3452463T3 (pl) 2021-08-09
JP6932140B2 (ja) 2021-09-08
CL2018003105A1 (es) 2019-02-15
ECSP18081881A (es) 2018-11-30
CU20180134A7 (es) 2019-06-04
CA3022749A1 (en) 2017-11-09
WO2017191102A1 (en) 2017-11-09
MA44851A (fr) 2019-03-13
TWI772295B (zh) 2022-08-01
PT3452463T (pt) 2021-04-28
DK3452463T3 (da) 2021-04-26
ES2866109T3 (es) 2021-10-19
US20200017473A1 (en) 2020-01-16
MX381787B (es) 2025-03-13
US11091463B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
US11091463B2 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
EP3452470B1 (en) Amide-substituted phenyltriazole derivatives and uses thereof
US10525041B2 (en) Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
US10526314B2 (en) Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
US20190119251A1 (en) Amide-substituted aryltriazole derivatives and uses thereof
EP3700897A1 (en) Substituted triazole derivatives and uses thereof
US11149023B2 (en) Substituted triazole derivatives and uses thereof
US11230540B2 (en) Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
HK40055794A (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
HK40005398B (zh) 酰胺取代的吡啶基三唑衍生物及其用途
HK40005398A (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
EP3452468A1 (en) Amide-substituted aryltriazole derivatives and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ COLLIN-KROPELIN, MARIE-PIERRE; KOLKHOF, PETER; NEUBAUER, THOMAS; FUERSTNER, CHANTAL; POOK, ELISABETH; WITTWER, MATTHIAS BEAT; LUSTIG, KLEMENS; BUCHMUELLER, ANJA; TINEL, HANNA; DROEBNER, KAROLINE; MONDRITZKI, THOMAS; SCHIRMER, HEIKO; KRETSCHMER, AXEL; SCHMECK, CARSTEN; WASNAIRE, PIERRE AND CERNECKA, HANA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired